In its main clinical trial, mRNA-1010 was shown to be 26.6% more effective than the comparator flu shot in adults aged 50 ...

The FDA’s refuse-to-file letter cited no safety or efficacy concerns for Moderna’s influenza vaccine, mRNA-1010. The company ...

The FDA has refused to review Moderna’s application for its messenger RNA-based influenza vaccine, according to the company.In a press release, Moderna noted that the FDA’s rejection of the vaccine, ...

The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu ...

In an interview, Moderna President Stephen Hoge took questions on an FDA decision on the biotech's mRNA flu vaccine, as well as the impact on the company and others in the industry.

Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the ...

An unnamed FDA official also told reporters that it would be good for Moderna to “show some humility” and admit that it ...

Correction: This story was updated to clarify a statement given by Department of Health and Human Services spokesperson Andrew Nixon. Moderna said on Tuesday that the Food and Drug Administration (FDA ...

[Dublin, Ireland, 16th February 2026] — Leading global healthcare services provider Uniphar today announced a strategic merger between Uniphar | Clinical and BMclinical, reinforcing Uniphar | Clinical ...

Selections from the show's 150+ education sessions, including our team’s top picks in equipment and technology.

Mani Foroohar, M.D., of Leerink Partners, says that the decision reflects “how sharp the departure has been between the prior ...

Patient-level digital twins expected to strengthen evidence generation in Phase1/2 clinical study evaluating VTx-002, a first ...